Executive Order Expedites Rescheduling of Marijuana for Medical Research and CBD Exploration
President Trump recently signed an executive order aimed at expediting the rescheduling of marijuana from Schedule I to Schedule III. The order is intended to facilitate cannabis research and increase medical research for medical marijuana and CBD. The administration is focused on exploring the potential medical benefits of these substances to better inform patients and doctors.
Under the Controlled Substances Act, Schedule I substances are considered to have no accepted medical uses, while Schedule III substances are believed to have a lower potential for dependence. The move to reschedule marijuana could have implications for businesses in the industry, allowing them to deduct expenses or receive tax credits on their federal taxes.
The executive order does not impact criminal penalties or recreational use of marijuana. While the administration is focused on medical research and potential benefits, there is no indication of any plans to expand recreational use at this time. The rescheduling process is expected to be expedited under the new directive, building on previous efforts initiated by the Biden administration.